Eiko Lifesciences Ltd
Fundamental Score
Eiko Lifesciences Ltd Share Price Live NSE/BSE
Profitability Metrics
Return on Equity
Return on Capital Employed
Operating Profit Margin (5Y)
Dividend Yield
Valuation Metrics
Price to Earnings
Market Capitalization
Industry P/E
Growth Metrics
YoY Quarterly Profit Growth
YoY Quarterly Sales Growth
Sales Growth (5Y)
EPS Growth (5Y)
Profit Growth (5Y)
Financial Health
Debt to Equity
Interest Coverage
Free Cash Flow (5Y)
Ownership Structure
Promoter Holding
FII Holding
DII Holding
Pledged Percentage
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Market Data Analysis & Educational Insights
Educational evaluation of EIKO across key market metrics for learning purposes.
Positive Indicators
9 factors identified
Attractive Valuation (P/E: 21.63 vs Industry: 29.20)
Observation: Trading at discount to industry peers.
Analysis: P/E below industry average may present value opportunity if fundamentals support the business case.
Robust Profit Growth (285.71%)
Observation: Strong year-over-year profit expansion demonstrates business momentum.
Analysis: Profit growth >20% indicates effective execution and market opportunity capture. This suggests positive business trajectory.
Strong Revenue Growth (43.01%)
Observation: Healthy sales growth indicates market demand and execution capability.
Analysis: Revenue growth >15% suggests strong market position and growth potential. This indicates business expansion success.
Consistent Growth Track Record (29.35% CAGR)
Observation: Strong 5-year sales compound annual growth rate.
Analysis: Consistent sales CAGR >12% demonstrates sustainable growth model and market opportunity execution over time.
Excellent EPS Growth (20.61% CAGR)
Observation: Outstanding 5-year earnings per share compound growth.
Analysis: EPS CAGR >15% indicates strong wealth creation potential and effective capital allocation over extended periods.
Strong Profit Growth Track Record (25.18% CAGR)
Observation: Consistent 5-year profit compound annual growth rate.
Analysis: Profit CAGR >15% demonstrates scalable business model and effective operational leverage over time.
Conservative Debt Levels (D/E: 0.02)
Observation: Low leverage provides financial flexibility and reduced risk.
Analysis: Conservative debt structure offers resilience during economic downturns and flexibility for growth investments.
Strong Interest Coverage (20.84x)
Observation: Earnings comfortably cover interest obligations.
Analysis: Interest coverage >5x indicates low financial distress risk and strong debt servicing capability.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral, reducing forced-selling risk.
Analysis: Absence of share pledging eliminates potential forced-selling pressure during market stress.
Risk Factors
2 factors identified
No Dividend Distribution
Observation: Company does not currently pay dividends to shareholders.
Analysis: Zero dividend yield may indicate growth reinvestment focus or cash flow constraints. Assess capital allocation strategy.
Small Market Cap
Observation: Higher investment risk due to limited size.
Analysis: Small-cap stocks typically carry higher volatility and liquidity risks.
Financial Statements
Comprehensive financial data for Eiko Lifesciences Ltd
About EIKO
Business Overview
Eiko LifeSciences Limited, together with its subsidiary, manufactures and sells specialty and fine chemicals in India and internationally. It operates through Agrochemicals; Oleo Chemicals; Pharmaceuticals; Food Additives; Clinical Research, Development; and Logistics segments. It also offers cosmetic emollients, and flavor and fragrances. In addition, the company is involved in manufacturing, suppling, and exporting of specialty chemicals, fine chemicals, and pharma intermediates; acquiring, manufacturing, leasing, and renting, and managing shipping containers; and clinical research, development, and innovation within the specialty chemicals, healthcare, and other medical fields. Its products are used in pharmaceuticals, agrochemicals, aroma chemicals, consumer goods, and electronic chemicals. The company also export its products. The company was formerly known as Narendra Investments (Delhi) Limited and changed its name to Eiko LifeSciences Limited in June 2021. Eiko LifeSciences Limited was incorporated in 1977 and is based in Thane, India.
Company Details
Key Leadership
Corporate Events
Latest News
EIKO Stock Details & Analysis
Key Financial Metrics
Growth & Valuation
Frequently Asked Questions
What is the current price of Eiko Lifesciences Ltd (EIKO)?
As of 29 Jan 2026, 10:38 am IST, Eiko Lifesciences Ltd (EIKO) is currently trading at ₹51.01. The stock has a market capitalization of ₹69.89 (Cr).
Is EIKO share price Overvalued or Undervalued?
EIKO is currently trading at a P/E ratio of 21.63x, compared to the industry average of 29.20x. Based on this relative valuation, the stock appears to be Undervalued against its sector peers.
What factors affect the Eiko Lifesciences Ltd share price?
Key factors influencing EIKO's price include its quarterly earnings growth (Sales Growth: 43.01%), raw material costs, government infrastructure spending, and institutional flows (FII/DII holding).
Is Eiko Lifesciences Ltd a good stock for long-term investment?
Eiko Lifesciences Ltd shows a 5-year Profit Growth of 25.18% and an ROE of N/A%. Long-term investors should consider these fundamentals alongside the debt-to-equity ratio of 0.02 before investing.
How does Eiko Lifesciences Ltd compare with its industry peers?
Eiko Lifesciences Ltd competes with major peers in the Specialty Chemicals. Investors should compare EIKO's P/E of 21.63x and ROE of N/A% against the industry averages to determine its competitive standing.
What is the P/E ratio of EIKO and what does it mean?
EIKO has a P/E ratio of 21.63x compared to the industry average of 29.20x. The Price-to-Earnings (P/E) ratio is calculated by dividing the current share price by earnings per share (EPS). This means investors are paying ₹22 for every ₹1 of annual earnings.
How is EIKO performing according to Bull Run's analysis?
EIKO has a Bull Run fundamental score of 51/100, which indicates moderate strength with some areas for improvement. This comprehensive rating is based on 15+ financial parameters including profitability, growth metrics, and valuation ratios.
What sector and industry does EIKO belong to?
EIKO operates in the Specialty Chemicals industry. This classification helps understand the competitive landscape and sector-specific trends affecting Eiko Lifesciences Ltd.
What is Return on Equity (ROE) and why is it important for EIKO?
EIKO has an ROE of N/A%, which suggests challenges in generating returns from shareholders' equity. Return on Equity measures how efficiently Eiko Lifesciences Ltd generates profits from shareholders' equity.
How is EIKO's debt-to-equity ratio and what does it indicate?
EIKO has a debt-to-equity ratio of 0.02, which indicates conservative financing with low financial risk. A ratio below 1.0 generally indicates conservative financing.
What is EIKO's dividend yield and is it a good dividend stock?
EIKO offers a dividend yield of 0.00%, which means you receive ₹0.00 annual dividend for every ₹100 invested.
How has EIKO grown over the past 5 years?
EIKO has achieved 5-year growth rates of: Sales Growth 29.35%, Profit Growth 25.18%, and EPS Growth 20.61%.
What is the promoter holding in EIKO and why does it matter?
Promoters hold 37.17% of EIKO shares, with 0.00% of promoter shares pledged. High promoter holding often indicates strong management confidence.
What is EIKO's market capitalization category?
EIKO has a market capitalization of ₹70 crores, placing it in the Small-cap category.
How volatile is EIKO stock?
EIKO has a beta of N/A. A beta > 1 suggests the stock is more volatile than the market, while a beta < 1 suggests it is less volatile.
What is the 52-week high and low for EIKO?
EIKO has a 52-week high of ₹N/A and low of ₹N/A.
What is EIKO's operating profit margin trend?
EIKO has a 5-year average Operating Profit Margin (OPM) of N/A%, indicating the company's operational efficiency.
How is EIKO's quarterly performance?
Recent quarterly performance shows YoY Sales Growth of 43.01% and YoY Profit Growth of 285.71%.
What is the institutional holding pattern in EIKO?
EIKO has FII holding of 0.00% and DII holding of 0.00%. Significant institutional holding often suggests professional confidence in the stock.